Home » Stocks » EARS

Auris Medical Holding Ltd. (EARS)

Stock Price: $5.23 USD 4.12 (371.17%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $3.99 -1.24 (-23.71%) Dec 1, 5:58 PM

Stock Price Chart

Key Info

Market Cap 37.08M
Revenue (ttm) n/a
Net Income (ttm) -6.63M
Shares Out 7.09M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $5.23
Previous Close $1.11
Change ($) 4.12
Change (%) 371.17%
Day's Open 1.46
Day's Range 1.32 - 6.60
Day's Volume 305,920,597
52-Week Range 0.70 - 6.60

More Stats

Market Cap 37.08M
Enterprise Value 35.69M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.09M
Float n/a
EPS (basic) -2.28
EPS (diluted) -1.33
FCF / Share -4.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 76,736
Short Ratio 0.03
Short % of Float n/a
Beta 0.37
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.37
Revenue n/a
Operating Income -7.26M
Net Income -6.63M
Free Cash Flow -8.46M
Net Cash 1.38M
Net Cash / Share 0.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -35.36%
ROE -84.67%
ROIC 402.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$15.88*
Low
15.9
Current: $5.23
High
15.9
Target: 15.88
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-7.26-11.47-25.39-30.22-30.88-22.19-14.62-4.61
Net Income-6.63-11.50-24.41-30.66-29.71-18.19-15.00-4.60
Shares Outstanding1.870.240.170.170.150.15--
Earnings Per Share-2.28-14.46-111.61-178.60-184.00-132.00-202.00-80.00
Operating Cash Flow-8.39-13.23-24.28-29.45-28.73-19.32-14.04-4.50
Capital Expenditures-0.060.07-0.01-0.24-0.08-0.11-0.11-0.13
Free Cash Flow-8.46-13.16-24.28-29.70-28.81-19.43-14.15-4.63
Cash & Equivalents1.385.3914.9732.4450.2456.9323.87-
Total Debt-1.4410.1312.36--13.71-
Net Cash / Debt1.383.964.8520.0850.2456.9310.15-
Assets9.239.8817.8335.6652.8159.4926.25-
Liabilities3.196.2319.9921.528.076.2117.22-
Book Value6.043.65-2.1614.1444.7453.289.03-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Auris Medical Holding Ltd.
Country Bermuda
Employees 8
CEO Thomas Meyer

Stock Information

Ticker Symbol EARS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EARS
IPO Date August 6, 2014

Description

Auris Medical Holding, a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.